title: The combination paclitaxel, carboplatin and megestrol acetate is effective in women with recurrent uterine papillary serous adenocarcinoma.
abstract: Uterine papillary serous adenocarcinoma is an uncommon and very aggressive type of endometrial cancer. A 76-year-old patient diagnosed with recurrent uterine papillary serous adenocarcinoma was prescribed megesterol acetate (160 mg daily), paclitaxel (135 mg/m2) and carboplatin (area under the concentration-time curve of 5) every 4 weeks for 4 courses. She demonstrated complete clinical response that was maintained for longer than 6 months with minimal toxicity. The combination megesterol acetate, paclitaxel and carboplatin may be effective in women with recurrent uterine papillary serous adenocarcinoma.
authors.affiliation: Division of Gynecologic Oncology, University of Vermont, Burlington 05401, USA.
authors.forename: G H
authors.initials: GH
authors.lastname: Eltabbakh
authors.forename: J
authors.initials: J
authors.lastname: Moody
authors.forename: L L
authors.initials: LL
authors.lastname: Garafano
authors.forename: J M
authors.initials: JM
authors.lastname: Hammond
mesh_terms: D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D016190:Carboplatin / Q000008:administration & dosage; D018283:Cystadenocarcinoma, Papillary / Q000188:drug therapy*; D016889:Endometrial Neoplasms / Q000188:drug therapy*; D005260:Female; D006801:Humans; D019290:Megestrol Acetate / Q000008:administration & dosage; D017239:Paclitaxel / Q000008:administration & dosage; D011379:Prognosis; D016896:Treatment Outcome
chemical_list: D016190:Carboplatin; D017239:Paclitaxel; D019290:Megestrol Acetate